MA45227A - Peptides pour le traitement de l'ostéoarthrite - Google Patents

Peptides pour le traitement de l'ostéoarthrite

Info

Publication number
MA45227A
MA45227A MA045227A MA45227A MA45227A MA 45227 A MA45227 A MA 45227A MA 045227 A MA045227 A MA 045227A MA 45227 A MA45227 A MA 45227A MA 45227 A MA45227 A MA 45227A
Authority
MA
Morocco
Prior art keywords
osteoarthritis
peptides
treatment
Prior art date
Application number
MA045227A
Other languages
English (en)
Inventor
Claude Carelli
Raffaello Paolini
Christelle Vêtu
Original Assignee
Regulaxis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulaxis filed Critical Regulaxis
Publication of MA45227A publication Critical patent/MA45227A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA045227A 2016-06-10 2017-06-09 Peptides pour le traitement de l'ostéoarthrite MA45227A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16174056 2016-06-10

Publications (1)

Publication Number Publication Date
MA45227A true MA45227A (fr) 2019-04-17

Family

ID=56132793

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045227A MA45227A (fr) 2016-06-10 2017-06-09 Peptides pour le traitement de l'ostéoarthrite

Country Status (12)

Country Link
US (1) US10813980B2 (fr)
EP (1) EP3468582A1 (fr)
JP (1) JP7010934B2 (fr)
KR (1) KR20190018466A (fr)
CN (1) CN109862905A (fr)
AU (1) AU2017277747A1 (fr)
BR (1) BR112018075613A2 (fr)
CA (1) CA3026984A1 (fr)
IL (1) IL263564B (fr)
MA (1) MA45227A (fr)
RU (1) RU2018145945A (fr)
WO (1) WO2017212057A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108785661A (zh) * 2018-07-20 2018-11-13 深圳市第二人民医院 一种无副作用治疗退行性骨关节病的注射剂及其制备方法
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
KR102856432B1 (ko) 2022-02-23 2025-09-08 중앙대학교 산학협력단 졸참나무 잎 추출물을 유효성분으로 포함하는 골관절염 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1208760B (it) * 1986-11-04 1989-07-10 Ind Farmaceutica Serono S P A Trattamento delle malattie infiammatorie articolari
FR2833012B1 (fr) 2001-12-04 2004-01-30 Centre Nat Rech Scient Peptides agonistes de l'hormone de croissance et leurs applications
US20040127402A1 (en) 2002-12-27 2004-07-01 Vad Vijay B. Injectible composition and method for treating degenerative animal joints
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20070184015A1 (en) 2006-02-03 2007-08-09 Soonkap Hahn Novel PEGylation agent
WO2010105685A1 (fr) 2009-03-19 2010-09-23 Universite Pierre Et Marie Curie Peptides destinés à inhiber l'igf-1
MX339484B (es) 2009-11-18 2016-05-27 Asahi Kasei Pharma Corp Agente preventivo y/o agente terapeutico y/o agente supresivo del agravamiento para la artritis humana deformante.

Also Published As

Publication number Publication date
IL263564B (en) 2021-07-29
KR20190018466A (ko) 2019-02-22
IL263564A (en) 2019-02-03
WO2017212057A1 (fr) 2017-12-14
CN109862905A (zh) 2019-06-07
RU2018145945A3 (fr) 2020-07-10
RU2018145945A (ru) 2020-07-10
US10813980B2 (en) 2020-10-27
CA3026984A1 (fr) 2017-12-14
JP7010934B2 (ja) 2022-02-10
AU2017277747A1 (en) 2019-01-17
JP2019522046A (ja) 2019-08-08
US20190298808A1 (en) 2019-10-03
BR112018075613A2 (pt) 2019-04-09
EP3468582A1 (fr) 2019-04-17

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3370721A4 (fr) Traitement de l'ostéoarthrite
MA45036A (fr) Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
EP3359074A4 (fr) Électroporation pour le traitement de l'obésité ou le diabète
EP3458106A4 (fr) Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
EP3233878A4 (fr) Phosphoramidates pour le traitement du virus de l'hépatite b
MA41449A (fr) Polythérapies pour le traitement de cancers
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3496662A4 (fr) Protéine dérivée de la soie pour le traitement d'une inflammation
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3766497A4 (fr) Médicament pour le traitement de la toux
MA45492A (fr) Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
EP3443962A4 (fr) Dérivé de quinoline pour le traitement du cancer de l'estomac